Search Results - masaru+kanekiyo

6 Results

Sort By:

Prefusion Coronavirus Spike Proteins and Their Use

Coronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in 8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has resulted in 2144 cases and over 750 deaths as of March 2018. Currently, there are no effective prophylactic or therapeutic measures, and because...

Published: 7/25/2024 | Inventor(s): Masaru Kanekiyo, Michael Joyce, Kizzmekia Corbett, Hadi Yassine, Jason McLellan, Christopher Cottrell, Nianshuang Wang, Jesper Pallesen, Hannah Turner, Robert Kirchdoerfer, Andrew Ward, Barney Graham

Keywords(s): CORONAVIRUS, DC5BXX, proteins, Stabilized, VACCINATION

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Vaccines

Novel Multivalent Nanoparticle Vaccines

Current seasonal influenza vaccines are designed to elicit immunity to circulating strains of influenza each year. The targeted strains are selected based on predictions of which strains are likely to be predominant in the human population for a given year. This prediction must be made well ahead of the influenza season to allow time for vaccine production...

Published: 7/25/2024 | Inventor(s): Masaru Kanekiyo, Hadi Yassine, Barney Graham

Keywords(s): ARRAY, Broader, DOMAINS, HEMAGGLUTININ, INFLUENZA, Listed LPM Thalhammer-Reyero as of 4/15/2015, MOSAIC, Nanoparticulate, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Receptor-Binding, Receptor-bindingdomains, Spectrum, Vaccine

Category(s): Collaboration Sought > Licensing

Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof

An effective universal influenza vaccine would eliminate the uncertain and costly process of seasonal influenza vaccine development each year. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) are developing immunogens which elicit neutralizing antibodies to the highly conserved stem region of the influenza viral protein...

Published: 7/25/2024 | Inventor(s): Jeffrey Boyington, Hadi Yassine, Peter Kwong, Masaru Kanekiyo, Barney Graham, John Mascola

Keywords(s): Broad, Development, ELICIT, HEMAGGLUTININ, IMMUNE, INFLUENZA, Listed LPM Thalhammer-Reyero as of 4/15/2015, Modified, Nanoparticles, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RESPONSE, Stem

Category(s): Collaboration Sought > Licensing

Novel Epstein-Barr Virus Vaccines

Epstein-Barr Virus (EBV) is the causative agent of infectious mononucleosis and is associated with certain types of cancers, such as Hodgkin's lymphoma, Burkitt's lymphoma, gastric carcinoma, and nasopharyngeal carcinoma. There are currently no vaccines against EBV on the market and there is only supportive treatment available for EBV infection. The...

Published: 7/25/2024 | Inventor(s): Wei Bu, Gary Nabel, Jeffrey Cohen, Masaru Kanekiyo

Keywords(s): D, DC5BXX, Development, EPSTEIN-BARR, Evelopment, Listed LPM Chang as of 4/15/2015, Nanoparticle-Based, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, vaccines, VCXXXX, virus, VLXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Application > Vaccines

Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine

The invention, a stabilized recombinant prefusion F protein (pre F), is a candidate subunit vaccine for Respiratory Syncytial Virus (RSV). Pre-F is stabilized in the prefusion conformation and displays epitopes not present in postfusion F protein. Several potent RSV neutralizing antibodies bind pre F, but not postfusion F. Therefore, immunization...

Published: 7/25/2024 | Inventor(s): Jason Gorman, Gilad Ofek, Marie Pancera, Mallika Sastry, Sanjay Srivatsan, Yongping Yang, Lei Chen, Cinque Soto, Tongqing Zhou, Barney Graham, Peter Kwong, Masaru Kanekiyo, Michael Joyce, Baoshan Zhang, Guillaume Stewart-Jones, Jeffrey Boyington, Man Chen, Gwo-Yu Chuang, Ivelin Georgiev, Jason McLellan

Keywords(s): CONFORMATION, DC5BXX, DC5XXX, DCXXXX, DXXXXX, F, GLYCOPROTEIN, Listed LPM Thalhammer-Reyero as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prefusion, PrefusionConformation, RSV, Stabilization, Structure-based, Vaccine, VLXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease

Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine

NIH inventors at the Vaccine Research Center have developed a novel influenza virus hemagglutinin (HA)-ferritin nanoparticle influenza vaccine that is easily manufactured, potent, and elicits broadly neutralizing influenza antibodies against multiple strains of influenza. This novel influenza nanoparticle vaccine elicited two types of broadly neutralizing,...

Published: 7/25/2024 | Inventor(s): Masaru Kanekiyo, Jeffrey Boyington, Gary Nabel

Keywords(s): assay, DC5BXX, DC5XXX, DCXXXX, Development, DXXXXX, Ferritin, HA-Ferritin, HEMAGGLUTINATION, HEMAGGLUTININ, INFLUENZA, inhibition, Nanoparticles, SELF-ASSEMBLING, Vaccine

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines